The effect of SGLT-2i on renal function in patients with diabetic kidney disease combined with metabolic syndrome
Objective To analyze the effect of sodium-glucose cotransporter protein 2 inhibitor(SGLT-2i)on glomerular filtration rate(eGFR)slope and prognosis in patients with diabetic kidney disease(DKD)combined with metabolic syndrome(MS).Methods One hundred and thirty patients with DKD combined with MS were divided into a conventional treatment combined with SGLT-2i group and a conventional treatment group according to the treatment methods.The eGFR slopes and prognosis were compared between the two groups.Results After more than 6 months of treatment,the high-density lipoprotein cholesterol(HDL-C)was higher and the blood uric acid,total cholesterol(TC),triglyceride(TG),and fasting glucose were lower in the combined group than those in the conventional group(P<0.05).The eGFR slope of the combined group was lower than that of the conventional group,and the difference of the eGFR slopes between the two groups was statistically significant(P<0.05).Survival analysis suggested that the com-bination group delayed the decline of eGFR(P<0.05).Multifactorial COX regression analysis showed that eGFR slope and blood uric acid were independent risk factors for the occurrence of renal endpoint events(P<0.05).Conclusions SGLT-2i can reduce the eGFR slope and improve the renal prognosis in patients with DKD combined with MS.eGFR slope and blood uric acid are independent risk factors for progression to renal endpoint events in patients with DKD combined with MS.
NETL
NSTL
万方数据
